Bird Flu Monitor > Bird Flu Update: Whole-Virus H5N1 Vaccine Tested Successfully
[Right Mind] In a combined phase 1 and 2 study designed and conducted largely by the manufacturer, nearly 300 volunteers in Singapore and Austria received various doses of the whole-virus vaccine. The vaccine was immunogenic both against the primary strain of H5N1 used in the vaccine as well as against two other strains of H5N1 tested.
Some related posts from Technorati and Google.
[Malaysian Medical Resources] Whole-Virus H5N1 Vaccine Tested Successfully: The vaccine was immunogenic both against the primary strain of H5N1 used in the vaccine as well as against two other strains of H5N1 tested. Pain at the injection site and headache were the two most common adverse reactions.
[InfectoNews - Jorge Omar Calabrese] A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell ...: Tambyah, M.B., B.S., Christian Joukhadar, M.D., Emanuele Montomoli, Ph.D., Dale Fisher, F.R.A.C.P., Greg Berezuk, M.S., Sandor Fritsch, Ph.D., Alexandra Löw-Baselli, Ph.D., Nina Vartian, Ph.D., Roman Bobrovsky, Ph.D., Borislava G. Pavlova, Ph.D., Eva Maria Pöllabauer, M.D., Otfried Kistner, Ph.D., P.
[KurzweilAI.net Accelerating Intelligence News] New Human H5N1 Bird Flu Vaccine From Baxter Shows Promise In Trial: ... safe and effective against a number of divergent strains. See also: A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture, New England Journal of Medicine (Source: http://www.medicalnewstoday.com/articles/110969.php)
[Health & fitness - health-fitness.marc8.com] Early Data Favorable for H5N1 Vaccine from Tissue-Culture Substr...: VIENNA -- An H5N1 whole-virus vaccine grown in tissue culture seems both safe and effective in a two-dose regimen against avian influenza, found a clinical trial of nearly 300 volunteers.
[Pathophilia] Avian Flu Vaccine Is Immunogenic and Safe in Early-Phase Trial: An inactivated, whole-virus H5N1 vaccine is immunogenic and safe, according to a Baxter-sponsored, -designed, and -analyzed study. The results of the phase 1/2 trial were reported in this week's NEJM.
[Modern Medicine] Vaccine Shows Promise Against H5N1 Avian Influenza: WEDNESDAY, June 11 (HealthDay News) -- Two doses of a whole-virus vaccine against H5N1 avian influenza produced on Vero cell cultures induced neutralizing antibodies against multiple H5N1 strains, indicating its usefulness against this virus with pandemic potential, according to research published in the June 12 issue of the New England Journal of Medicine.
[Healthy Living] New Bird Flu Vaccine Shows Promise: In the past two years, the H5N1 strain of avian flu has infected poultry throughout Southeast Asia, Central Asia, Africa and Europe, prompting the destruction of millions of birds. So far, more than 100 people have died worldwide from H5N1 infection, which has been spread through close contact with birds.
[Elsevier Global Medical News - US Top Stories] Whole-Virus Bird Flu Vaccine Produced in Cell Culture: A whole-virus vaccine against several H5N1 strains that was produced in cell culture instead of in embryonated eggs has passed the first hurdle of human safety and immunogenicity testing, according to a report by the manufacturer in the .
[Pharmaceutical Engineering] Whole-virus formulation leads to dose-sparing H5N1 vaccine: 15/09/2006 - Chinese researchers may have solved the problem of vaccine shortage in the event of an avian influenza pandemic after a clinical trial showed that their formulation containing the whole H5N1 virus instead of virus particles resulted in an affective immune response at lower doses.
[Medical News and Health News Blog] Baxter Announces Preliminary Phase I/II Data For Seasonal ...: In the 18-49 subject population, 99.6 percent achieved protective antibody levels for virus strains H1N1 and H3N2, and 92.9 percent for strain B. In the 50 years of age and older population, 96.6 percent achieved protective levels for virus strain H1N1, 100 percent for H3N2 and 73.3 percent for strain B.
[Health Blog] Baxter Announces Safety And Immunogenicity Results From Phase I/II ...: (NYSE: BAX) today announced results from a preliminary evaluation of its Phase I/II clinical trial of whole-virus H5N1 influenza candidate vaccine. The results represent the first clinical evaluation of a vero cell-based candidate H5N1 .
[Global News Blog] China - Chinese concerned by missile testing: Chinese H5N1 trial points to whole-virus formula as way to stretch 680 News - (CP) - A Chinese-made H5N1 flu vaccine has been shown to provoke good immune responses at significantly lower doses than those made by most western vaccine .
Reflected tags on Technorati: Blog, H5n1, Bird Flu Monitor